InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system, has announced inducement grants for nine new non-executive employees. The Compensation Committee approved a total of 372,135 shares of restricted stock outside the company's 2021 Equity Compensation Plan, with a grant date of January 7, 2025.
The restricted stock grants are structured with a three-year vesting period: one-third vests after the first year, with the remaining shares vesting equally on the second and third anniversaries of the grant date. These grants, made under Nasdaq Listing Rule 5635(c)(4), are specifically designed as employment inducements for new hires who were not previously InspireMD employees.
InspireMD (NSPR), sviluppatore del sistema di stent carotideo CGuard™ Prime, ha annunciato concessioni d'induzione per nove nuovi dipendenti non esecutivi. Il Comitato per la Compensazione ha approvato un totale di 372.135 azioni di azioni bloccate al di fuori del Piano di Compensazione in Azioni 2021 dell'azienda, con una data di concessione del 7 gennaio 2025.
Le concessioni di azioni bloccate sono strutturate con un periodo di maturazione di tre anni: un terzo matura dopo il primo anno, mentre le restanti azioni maturano equamente nei secondi e terzi anniversari della data di concessione. Queste concessioni, effettuate ai sensi della Regola di Listing Nasdaq 5635(c)(4), sono specificamente progettate come indumenti occupazionali per nuovi assunti che non erano precedentemente dipendenti di InspireMD.
InspireMD (NSPR), desarrollador del sistema de stent carotídeo CGuard™ Prime, ha anunciado subvenciones de inducción para nueve nuevos empleados no ejecutivos. El Comité de Compensación aprobó un total de 372,135 acciones de acciones restringidas fuera del Plan de Compensación en Acciones 2021 de la compañía, con una fecha de otorgamiento del 7 de enero de 2025.
Las concesiones de acciones restringidas se estructuran con un período de adquisición de tres años: un tercio adquiere derechos después del primer año, mientras que las acciones restantes adquieren derechos de manera equitativa en los segundos y terceros aniversarios de la fecha de otorgamiento. Estas concesiones, realizadas bajo la Regla de Cotización Nasdaq 5635(c)(4), están específicamente diseñadas como incentivos de empleo para nuevas contrataciones que no eran anteriormente empleados de InspireMD.
InspireMD (NSPR)는 CGuard™ Prime 경동맥 스텐트 시스템의 개발자로서 새로운 비상근 직원 9명에 대한 유도 보상안을 발표했습니다. 보상위원회는 2021년 주식 보상 계획 외에서 총 372,135주의 제한주식을 승인했으며, 부여일은 2025년 1월 7일입니다.
제한주식 보상은 3년의 가득 기간을 기준으로 구성됩니다: 1년 후 1/3이 자격을 획득하고, 나머지 주식은 부여일의 두 번째 및 세 번째 기념일에 동일하게 가득됩니다. 이러한 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어지며, InspireMD 직원이 아니었던 신규 직원에 대한 근로 유도책으로 특별히 설계되었습니다.
InspireMD (NSPR), développeur du système de stent carotidien CGuard™ Prime, a annoncé des subventions d'incitation pour neuf nouveaux employés non exécutifs. Le Comité de Rémunération a approuvé un total de 372.135 actions d'actions restreintes en dehors du Plan de Rémunération en Actions 2021 de l'entreprise, avec une date de concession du 7 janvier 2025.
Les subventions d'actions restreintes sont structurées avec une période d'acquisition de trois ans : un tiers s'acquiert après la première année, les actions restantes s'acquièrent de manière égale aux deuxième et troisième anniversaires de la date de concession. Ces subventions, effectuées selon la Règle de Cotation Nasdaq 5635(c)(4), sont spécifiquement conçues comme des incitations à l'emploi pour les nouvelles recrues qui n'étaient pas précédemment des employés d'InspireMD.
InspireMD (NSPR), Entwickler des CGuard™ Prime Carotisstentsystems, hat Induktionszuschüsse für neun neue nicht-executive Mitarbeiter angekündigt. Der Vergütungsausschuss genehmigte insgesamt 372.135 Aktien von eingeschränkten Aktien außerhalb des Aktienvergütungsplans 2021 des Unternehmens mit einem Gewährungsdatum vom 7. Januar 2025.
Die Zuschüsse für eingeschränkte Aktien sind mit einer drei Jahre dauernden Vestingperiode strukturiert: Ein Drittel wird nach dem ersten Jahr fällig, die übrigen Aktien vesten gleichmäßig an den zweiten und dritten Jahrestagen des Gewährungsdatums. Diese Zuschüsse, die unter der Nasdaq-Börsennotierungsregel 5635(c)(4) gemacht wurden, sind speziell als Anreize für neue Einstellungen konzipiert, die zuvor keine Mitarbeiter von InspireMD waren.
- Expansion of workforce with nine new non-executive employees indicates company growth
- Structured vesting schedule over three years helps retain talent
- Potential dilution of existing shareholders through issuance of 372,135 new shares
Insights
The inducement grants represent a strategic move in InspireMD's talent acquisition efforts, with 372,135 restricted shares allocated to nine new employees. Given NSPR's current market cap of
The structure of one-third vesting in the first year followed by two equal installments helps reduce immediate dilution while providing meaningful incentives. At current market prices, this compensation package demonstrates InspireMD's commitment to attracting quality talent in the competitive medical device sector, particularly for their CGuard™ Prime carotid stent system program. The use of equity compensation rather than cash preserves working capital, though shareholders should note the dilutive effect of approximately
MIAMI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to nine new non-executive employees in the aggregate amount of 372,135 shares of restricted stock outside of InspireMD’s 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
The restricted stock vests over a three-year period, with one-third vesting on the first anniversary of the grant and the remainder vesting in two equal installments on the second and third anniversaries of the grant date, subject to continued employment with InspireMD as of such vesting dates.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.
We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements regarding InspireMD or its management team’s expectations, hopes, beliefs, intentions or strategies regarding future events, future financial performance, strategies, expectations, competitive environment and regulation, including potential U.S. commercial launch. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” “scheduled” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with our history of recurring losses and negative cash flows from operating activities; substantial doubt about our ability to continue as a going concern; significant future commitments and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; our need to raise additional capital to meet our business requirements in the future and such capital raising may be costly or difficult to obtain and could dilute out stockholders’ ownership interests; market acceptance of our products; an inability to secure and maintain regulatory approvals for the sale of our products; negative clinical trial results or lengthy product delays in key markets; our ability to maintain compliance with the Nasdaq listing standards; our ability to generate revenues from our products and obtain and maintain regulatory approvals for our products; our ability to adequately protect our intellectual property; our dependence on a single manufacturing facility and our ability to comply with stringent manufacturing quality standards and to increase production as necessary; the risk that the data collected from our current and planned clinical trials may not be sufficient to demonstrate that our technology is an attractive alternative to other procedures and products; intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; entry of new competitors and products and potential technological obsolescence of our products; inability to carry out research, development and commercialization plans; loss of a key customer or supplier; technical problems with our research and products and potential product liability claims; product malfunctions; price increases for supplies and components; insufficient or inadequate reimbursement by governmental and other third-party payers for our products; our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful; adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions; the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction; the escalation of hostilities in Israel, which could impair our ability to manufacture our products; and current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Chuck Padala, Managing Director
LifeSci Advisors
646-627-8390
chuck@lifesciadvisors.com
investor-relations@inspiremd.com
FAQ
How many shares of restricted stock did InspireMD (NSPR) grant as inducement awards in January 2025?
What is the vesting schedule for NSPR's January 2025 inducement grants?
When were the NSPR inducement grants approved and under which Nasdaq rule?
Are NSPR's January 2025 inducement grants part of their 2021 Equity Compensation Plan?
